Clinical Trials

Filter by condition

12 studies in Department of Urology

  1. Virtue® Male Sling Fixation Study

    Phoenix/Scottsdale, Ariz. View Summary

    Virtue® Male Sling Fixation Study

    Location:

    Phoenix/Scottsdale, Ariz.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    This study is a multi-center study that will assess the efficacy and safety of suture fixation of the Virtue® Male Sling.

    NCT ID:

    NCT01170728

    Who can I contact for additional information about this study?


    Scottsdale: Andre Watkins, MPH 480-342-0349
                        

  2. Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine

    Rochester, Minn. View Summary

    Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    OBJECTIVES: Primary - To determine the safety and tolerance of Ad5CMV-NIS administered intraprostatically followed by radioiodine treatment in patients with locally recurrent adenocarcinoma of the prostate following external beam radiotherapy. - To determine the maximum tolerated dose of Ad5CMV-NIS in these patients. Secondary - To evaluate the PSA response rates, duration, and time to PSA progression in these patients. - To evaluate the immune response to Ad5CMV-NIS. OUTLINE: This is a dose-escalation study of Ad5CMV-NIS. Patients receive intraprostate Ad5CMV-NIS, via transperineal injection under anesthesia, on day 1. They receive dosimetry oral iodine I 123 on day 4 and undergo image studies periodically for the next 24 hours for measurement of radioiodine uptake. Patients receive therapeutic oral iodine I 131 on day 5. All patients with intact thyroid glands (i.e., not previously surgically removed or ablated) receive TSH suppressive doses of oral liothyronine sodium 3 times daily for 10 days prior and for 15 days post administration of iodine I 123. Blood samples are collected periodically for measurement of PSA, fT4, and TSH; and peripheral blood cells are monitored for evidence of virus DNA via quantitative reverse-transcriptase-PCR. After completion of study therapy, patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 8 years. A transrectal tumor biopsy is to be performed at 3 months and 1 year post-treatment.

    NCT ID:

    NCT00788307

    IRB Number:

    06-009392

    Who can I contact for additional information about this study?

    Rochester: Mayo Clinic Clinical Trials Office 855-776-0015
                        


  1. Prev
  2. 1
  3. 2